Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CardioMEMS Has Better Luck With FDA Advisory Panel Second Time Around

This article was originally published in The Gray Sheet

Executive Summary

FDA’s Circulatory System Devices panel wrestled with a new analysis of the CHAMPION trial of the Champion heart failure monitor Oct. 9. CardioMEMS was banking that the new analysis would eliminate the doubts about possible bias that undermined the company’s first effort to earn FDA approval in 2011.


Related Content

St. Jude To Acquire CardioMEMS As FDA Approves Heart Failure Monitor
CMS Skeptical Of Watchman, CardioMEMS Data For New-Tech Add-Ons
CMS Announces FY 2015 New-Tech Add-On Payment Applicants
St. Jude First To Market Leadless Pacemaker With Nanostim Buy
$18.4 Million In User Fees Left In CDRH’s Coffers, How Long Will It Last?
FDA Advisors Vote That Benefits Of Abbott’s MitraClip Outweigh Risks
CardioMEMS’ Heart Failure Monitor Foiled At Panel By FDA Inspection Findings Of Study Bias
St. Jude: CardioMEMS’ Heart Failure Data Reflects Major Opportunity


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts